Skip to main content
. Author manuscript; available in PMC: 2018 Mar 5.
Published in final edited form as: Br J Haematol. 2016 Dec 16;176(5):750–758. doi: 10.1111/bjh.14477

Table 1.

Patient characteristics at the time of first progression/relapse

PTCL-NOS AITL
N 135 105
Median age, years (range) 55 (23–79) 64 (28–83)
Gender Male 93 (69) 56 (53)
Performance status 2–4 28 (29) 17 (22)
Stage 3–4 75 (78) 72 (92)
Lactate dehydrogenase Above normal 46 (48) 34 (44)
Bone marrow involvement Present 40 (42) 34 (44)
Albumin Median (range) 3.8 (1.3–4.8) 3.9 (1.8–4.9)
Beta-2 microglobulin Median (range) 3.6 (1.6–12.4) 3.7 (1.7–9.3)
First line chemotherapy CHOP 79 (56) 80 (76)
Etoposide-containing regimen 17 (16) 10 (9)
HCVAD, HCVIDD 26 (19) 9 (9)
Others 13 (9) 6 (6)
Prior stem cell transplant Autologous/Allogeneic 10/1 8/0
Duration of response to first line therapy < 6 months 69 (51) 24 (23)
6 – 12 months 42 (31) 39 (37)
≥ 12 months 24 (18) 42 (40)
International Prognostic Index Low 32 (33) 12 (16)
Low-Intermediate 23 (24) 34 (45)
Intermediate-High 26 (27) 20 (26)
High 15 (16) 10 (13)
PIT Group 1 13 (14) 6 (8)
Group 2 34 (35) 28 (36)
Group 3 28 (29) 28 (36)
Group 4 21 (22) 15 (20)
Response to first line therapy CR 51 (38) 62 (59)
PR 25 (19) 16 (15)
SD/PD 53 (39) 25 (24)

AITL, angioimmunoblastic T-cell lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CR, complete response, HCVAD, hyper-fractionated cyclophosphamide, vincristine, dexamethasone, doxorubicin; HCVIDD, hyper-fractionated cyclophosphamide, vincristine, dexamethasone, liposomal doxorubicin; PD, progressive disease; PIT, prognostic index for PTCL-NOS; PR, partial response; PTCL-NOS, peripheral T-cell lymphoma-not otherwise specified; SD, stable disease